Clinical Trial Update: Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) [Phase 3]

View source ↗

Summary

Phase 3 trial of eflornithine plus sulindac for familial adenomatous polyposis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• eflornithine plus sulindac

Snippet

Sponsor: Cancer Prevention Pharmaceuticals, Inc. | Conditions: Familial Adenomatous Polyposis | Phase 3 | Status: COMPLETED | Results posted: 2021-06-08